Urine Opiates (OPI) Screen Flex Reagent Cartridge, Catalog No. DF 90A
510(k) K000464
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK000464 | Date14 Apr 2000 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- DJG
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3650
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 23 Sep 2026
The Urine Opiates (OPI) Screen Flex Reagent Cartridge is an enzyme immunoassay test system. It is designed for the qualitative or quantitative detection of opiate drugs and their metabolites in clinical urine specimens.
This device is supplied as a reagent cartridge for use in clinical toxicology settings. It is regulated under 21 CFR 862.3650 and has received FDA 510(k) clearance.
Other devices from Dade Behring, Inc.
Questions
AI-generated answers, 23 Sep 2026
What is the primary purpose of the Urine Opiates Screen Flex Reagent Cartridge?
This device is designed for use in clinical toxicology settings to perform qualitative or quantitative detection of opiate drugs and their metabolites in human urine specimens.
How is this device supplied for clinical use?
The device is supplied as a reagent cartridge, catalog number DF 90A, specifically engineered for integration into clinical toxicology testing systems.
What is the regulatory status of this reagent cartridge?
The device is regulated under 21 CFR 862.3650 and has received FDA 510(k) clearance for its intended use in clinical toxicology.